<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056754</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQL-ABTL</org_study_id>
    <nct_id>NCT04056754</nct_id>
  </id_info>
  <brief_title>Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer</brief_title>
  <official_title>A Randomised, Double-Blind, Multicentre Phase Ⅲ Study to Evaluate Abiraterone Acetate Versus Placebo Combined With Prednisone in Subjects With Asymptomatic or Mild Symptoms Without Chemotherapy, Metastatic Castration Resistant Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abiraterone acetate is an orally effective CYP17 inhibitor, which is metabolized into
      abiraterone in the body, and its inhibitory activity against CYP17 is 10-30 times that of
      ketoconazole. Clinical studies have shown that abiraterone acetate can significantly reduce
      the level of prostate specific antigen (PSA) in PCa patients, and help to reduce tumors,
      extending the lifespan of patients with advanced PCa for several years, and the toxicity is
      acceptable.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2014</start_date>
  <completion_date type="Actual">July 16, 2019</completion_date>
  <primary_completion_date type="Actual">March 14, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to PSA progression (TTPP）</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>The time interval between the administration of the drug and the progression of serum prostate specific antigen (PSA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen remission time</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>It was ≥50% lower than the baseline, and was confirmed as remission after re-testing after ≥4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>The percentage of participants with a best overall response defined as complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>The ECOG scoring standard is an indicator of the general health status and tolerance to treatment from the patient's physical strength. ECOG physical status score standard from 0 to 5. Starting with the dose until the score increases from the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Time from date of randomization to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To pain progression time</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Time from the start of medication to the progression of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment scale (FACT-P)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) total score, Functional Assessment of Cancer Therapy- General (FACT-G) total score, trial outcome index, functional well-being, physical well-being, prostate cancer subscale, and Functional Assessment of Cancer Therapy (FACT) Advanced Prostate Symptom Index-6 (FAPSI-6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen remission rate</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>The remission rate was defined as the proportion of remissions to the total number of people.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">268</enrollment>
  <condition>Metastatic Castration Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Abiraterone acetate group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group administered 4 tablets abiraterone acetate once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this group administered 4 tablets abiraterone acetate blank analog tablet once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.</description>
    <arm_group_label>Abiraterone acetate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Subjects administered 5mg prednisone twice daily in 28-day cycle.</description>
    <arm_group_label>Abiraterone acetate group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1.18 years and older, Eastern Cooperative Oncology Group (ECOG) performance status of 0
        to 1, Life expectancy ≥ 6 months.

        2. Prostate cancer. 3. Serum testosterone &lt;50 ng/dL (or 1.7 nmol/L). 4. Prostate cancer
        progression or lesion metastasis. 5. Restriction of antiandrogen therapy. 6. Restriction of
        Radiation therapy. 7. The treatment period of ketoconazole for prostate cancer was not
        exceed 7 days.

        8. Has not used opioid analgesics and azole drugs within 4 weeks before the first dose.

        9. Question 3 of the Concise Pain Questionnaire (BPI-SF) scored from 0-3 points.

        10. Adequate laboratory indicators. 11. Must be able to swallow tablets. 12. No pregnant or
        breastfeeding women, and a negative pregnancy test. 13. Understood and signed an informed
        consent form.

        Exclusion Criteria:

          1. Prostate pathology results are neuroendocrine prostate cancer.

          2. Has received cytotoxic chemotherapy or biological therapy for metastatic castration
             resistant prostate cancer.

          3. Has contraindications to the use of prednisone.

          4. A chronic disease that exceeds the prednisone dose in the study.

          5. Uncontrolled high blood pressure.

          6. Active or symptomatic viral hepatitis or other chronic liver disease.

          7. Visceral metastasis or brain metastasis.

          8. Pituitary or adrenal dysfunction.

          9. Active autoimmune diseases require the use of hormone therapy.

         10. Clinically significant heart disease.

         11. Participated in other clinical trials within 4 weeks.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun-Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Military Region Wuhan General Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TongJi medical college of HuaZhong University of Science &amp; Technology Affiliated TongJi Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Medical College Affiliated Huadong Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RenJi Hospital of Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhenjiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>August 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

